PA007527.r1: In Vivo Grade Recombinant Anti-mouse VEGFR-2 Monoclonal Antibody (Clone: DC101), Rat IgG1 Kappa
The in vivo grade recombinant anti-mouse VEGFR-2 rat IgG1 monoclonal antibody (clone of DC101) was produced in mammalian cells.
Applications: Western blot, immunoprecipitation (IP), Flow Cytometry (FC), and various in vitro and in vivo functional assays.PA007531.r1: Recombinant Anti-mouse VEGFR-2 Monoclonal Antibody (Clone: DC101), Rat IgG1 Kappa
Recombinant Rat IgG1 Monoclonal Antibody.
Conjugation: non-conjugated.
Specificity/Sensitivity: The recombinant VEGFR-2 monoclonal antibody (clone: DC101) specifically binds to the mouse VEGFR-2.
Applications: Flow cytometry (FC), and Immunohistochemistry - Frozen (IHC-F).
PA007531.h1Fs: Recombinant Anti-mouse VEGFR-2 Monoclonal Antibody (Clone: DC101), Human IgG1 Fc Silent Kappa
Recombinant Human IgG1 Monoclonal Antibody.
Conjugation: non-conjugated.
Specificity/Sensitivity: The recombinant VEGFR-2 monoclonal antibody (clone: DC101) specifically binds to the mouse VEGFR-2.
Applications: Flow cytometry (FC), and Immunohistochemistry - Frozen (IHC-F).
C061P: Ramucirumab Biosimilar, Human VEGFR2 Monoclonal Antibody
Recombinant Human IgG1 Monoclonal Antibody.
Specificity/Sensitivity: The monoclonal antibody ramucirumab biosimilar specifically binds to the human VEGFR2 (KDR).
Applications: ELISA, flow cytometry, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by ramucirumab.BP000995-PKA-242: Recombinant Human VEGFR2
Source:Insect Cells-derived.
The activity of VEGFR2 D1-7 was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces receptors. The ED50 for this effect is typically 10.0 ng/ml, corresponding to a specific activity of 100,000 IU/mg.
Purity > 95%, by SDS-PAGE.BP000995-PKA-243: Recombinant Human VEGFR2 Fc Chimera
Source:Insect Cells-derived.
The activity of sVEGFR-2/Fc was determined by its ability to inhibit the VEGF-dependent proliferation of human umbilical vein endothelial cells. The ED50 for this effect is typically 10-30 ng/ml, corresponding to a specific activity of 33,333.33-100,000 units/mg.
Purity > 90%, by SDS-PAGE.